Effects of montelukast on quality of life in patients with persistent allergic rhinitis

Otolaryngology - Head and Neck Surgery (United States)

Volumn 142, Issue 5, 2010, Pages 654-658

  Cingi, Cemal ^a   Ozlugedik, Samet ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EMOTION; EYE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; SLEEP; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; TABLET;

ACETATES; ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUALITY OF LIFE; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL; TABLETS; TREATMENT OUTCOME;

EID: 77951927101     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1016/j.otohns.2010.01.016     Document Type: Article

References (20)

1. Nathan RA, Meltzer EO, Selner JC, et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S808-14.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334.
3. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94:182-8.
4. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13.
5. Simoens S, Laekeman G. Pharmacotherapy of allergic rhinitis: a phar-maco-economic approach. Allergy 2009;64:85-95.
6. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003;90:182-90.
7. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55:7-16. (Pubitemid 32095164)
8. Okuda M, Watase T, Mezawa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
9. Numata T, Konno A, Yamakoshi T, et al. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999;108:467-73. (Pubitemid 29231077)
10. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105: 917-22. (Pubitemid 30324400)
11. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of monte-lukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88: 592-600. (Pubitemid 36183813)
12. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32: 1020-8. (Pubitemid 34779597)
13. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83.
14. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Controlled Clin Trials 1989;10:407-15.
15. Juniper EF, Guyatt GH, Willian A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7. (Pubitemid 24034293)
16. Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551-7. (Pubitemid 43010482)
17. Jiang RS. Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. J Otolaryngol 2006;35:117-21.
18. Hung CH, Hua YM, Hsu WT, et al. Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis. Pediatr Int 2007;49:322-7.
19. Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag 2007;3:327-32. (Pubitemid 46881460)
20. Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006;17: 49-54.